Navigation Links
Neurocrine Biosciences Presents Elagolix Data
Date:6/16/2009

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that data from Phase I and Phase II elagolix trials and preclinical work was presented at the 91st Annual Meeting of the Endocrine Society (ENDO 09) in Washington DC, June 10-13, 2009.

The first clinical abstract presentation at ENDO 09 reviews the results of a Phase I study in which elagolix was evaluated over six weeks (42 days) in 60 healthy premenopausal women. The study was a double-blind, placebo-controlled study in parallel groups in which 88% of the participants completed the treatment period. The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and endocrine effects of elagolix. The results of this study showed that daily administration of elagolix induced partial suppression of gonadotropins for 12-18 hours per day with a return to baseline each morning for 42 days. The effect on gonadotropins translated in a dose related fashion to maintenance of low estradiol levels over the six week period without inducing severe hot flashes or excessive bone resorption as determined by n-telopeptide. Consistent pharmacokinetic profiles were maintained throughout the 42 days of treatment, and adverse events were comparable among the placebo and elagolix groups.

The second clinical abstract at ENDO 09 reports results from a Phase II study where the safety of elagolix was evaluated in 252 women with a confirmed diagnosis of endometriosis. The study was a randomized, double-blind study of elagolix and depo-subQ provera 104 (used as an active control) administered over six months followed by six months of additional assessments. The primary endpoint of the study was to assess the impact of elagolix on bone mineral density using dual energy x-ray absorptiometry (DXA) scanning at months six and twelve. The
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Reports First Quarter 2008 Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
7. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
9. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... 8 Cost reductions offset a recession-driven ... AHPI ) narrowly back into profitability in the second ... quarter ended December 31, 2009 declined almost ... the same quarter last year to $11.4 million ... sales were reduced even more sharply, from approximately ...
(Date:2/8/2010)... N.J. , Feb. 8 Savient ... the company will release financial results for the fourth ... market on Thursday, February 25, 2010 . ... Group Vice President and Chief Financial Officer, will host ... a.m. Eastern Time on February 26, 2010 ...
(Date:2/8/2010)... BETHESDA, Md. , Feb. 8 Hanger ... that it plans to report its results of operations for ... Wednesday, February 10, 2010 . ,, The Company plans to ... ended December 31, 2009 on Wednesday, February ... conference call is scheduled to begin at 9:00 a.m., ...
Breaking Medicine Technology:Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2Diabetes cases to double and costs to triple by 2034 62179 1Diabetes cases to double and costs to triple by 2034 62179 2Diabetes cases to double and costs to triple by 2034 62179 3Nanowires key to future transistors electronics 14983 1Nanowires key to future transistors electronics 14983 2Nanowires key to future transistors electronics 14983 3Research sheds light on workings of anti cancer drug 62178 1Research sheds light on workings of anti cancer drug 62178 2Research sheds light on workings of anti cancer drug 62178 3
(Date:2/9/2010)... found larger, for-profit hospitals more likely to insert them ... and those that are set up to make a ... patients with advanced dementia, despite evidence that the practice ... and other problems. , "Our results suggest that decisions ... go to than a decision-making process that really elicits ...
(Date:2/9/2010)... Warns Against Insurer-favored ,Cost Solution,: Selling Policies That Amount ... ,, WASHINGTON , Feb. 9 /PRNewswire-USNewswire/ ... and regulators with its premium hikes of up to ... the face of questions from the White House and ... and state lawmakers should act to regulate health insurance ...
(Date:2/9/2010)... , Feb. 9 In conjunction with ... Laser Spine Institute (LSI) sponsored the first-annual Gridiron Greats ... Assistance Fund hosted by Mike Ditka and ... players and coaches, Gridiron Greats is a non-profit organization that ... in crisis. ,, This year, Gridiron Greats recognized LSI ...
(Date:2/9/2010)... are bred in captivity primarily for their skins, but ... their meat. A study shows that eating these animals ... wisdom of eating this ,delicacy., , Parasites, bacteria and ... metals and residues of veterinary drugs- eating reptile meat ... conclusion of a study published in the International ...
(Date:2/9/2010)... Health Freedom Act Could See Idaho Lose $1.6 Billion ... BOISE, Idaho , Feb. 9 As ... oppose a non-existent federal health care law, the long-term effects ...  AARP is calling the Idaho Health Freedom Act (House Bill ... signed into law, could see Idaho lose nearly ...
Breaking Medicine News(10 mins):Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2Health News:Study carried out into biological risks of eating reptiles 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4
... ORLEANS, May 6 Litigation surrounding health and damage ... June 18 conference to be held in New Orleans. ... law firm Baron & Budd, according to HB Litigation ... teleconferences on the subject, one for insurance attorneys and ...
... three genetic ties to brain metastasis, , , WEDNESDAY, May 6 ... breast cancer to the brain have been identified by U.S. ... treatments. , The spread, or metastasis, of breast cancer to ... been removed. Experts say this suggests that the cancer cells ...
... 6 Two scientists whose work has led to ... muscular dystrophy have been chosen to receive the 2009 ... Ph.D. and Louis M. Kunkel, Ph.D., share the 2009 ... the genes and proteins that cause muscular dystrophy, a ...
... May 6 The National Hospice and Palliative Care ... of Health and Human Services. Her Senate confirmation ... day in office, was the final appointment to President,s ... at the helm of HHS at a time when ...
... Former McKesson executive to lead further innovation of ... government agencies and wellness companiesBEDFORD, Mass., May 6 ... management software solutions, today announced that Bill Wisotzkey ... and design, effective immediately. Wisotzkey has more than ...
... $1.5 Million - $3 MillionPRINCETON, N.J., May 6 ... DSCI), a manufacturer and marketer of advanced wound care products, ... private label adhesive bandages to one of the largest medical ... are expected to range between $1.5 to $3.0 million for ...
Other Medicine News:Health News:HB Litigation Conferences Announces Conference and Two Teleconferences on Chinese Drywall Litigation and Insurance 2Health News:Genes Linked to Spread of Breast Cancer 2Health News:March of Dimes Awards $250,000 Prize to Scientists Unraveling the Causes of Muscular Dystrophy 2Health News:NHPCO Welcomes Kathleen Sebelius as HHS Secretary 2Health News:Casenet Names Bill Wisotzkey Vice President of Product Management and Design 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 3
... innovative design, the Burton 7500-I refractor delivers ... At Burton, we set out not only ... innovative concept, but to set the industry ... and stringent testing, we devote more resources ...
... The Company has developed the patented ... the LASIK procedure. Management and industry experts ... keratotomy instrument, or microkeratome, currently used in ... cadaver eye studies, the Company has demonstrated ...
3.5v Ophthalmic Diagnostic Set with AutoStep Coaxial Ophthalmoscope, Spot Retinoscope, Rechargeable Handle, and Soft Case. High-quality eyecare from the preferred name in diagnostic instruments....
3.5v Ophthalmic Diagnostic Set with Diagnostic Ophthalmoscope, Spot Retinoscope, Rechargeable Handle, and Soft Case. High-quality eyecare from the preferred name in diagnostic instruments....
Medicine Products: